While current guidelines recommend germline BRCA1/2 testing for all women diagnosed with epithelial ovarian cancer [7], our data suggest that with appropriate validation and high technical standards, a tumor‐first testing model may be a viable option to detect both somatic and germline variants. Here, BRCA1 is linked to neoplasm.